"name","text","uuid:ID","instanceType","description","label","id"
"OBJ1","To determine if there is a statistically significant relationship (overall Type 1 erroralpha=0.05) between the change in both the ADAS-Cog (11) and CIBIC+ scores, and drug dose (0, 50 cm2 [54 mg], and 75 cm2 [81 mg]).","e7ad886f-a988-4d41-94b1-959cd9267bc2","Objective","Main objective","","Objective_1"
"OBJ2","To document the safety profile of the xanomeline TTS.","d876b54c-35d9-425c-97af-4b27eca6232a","Objective","Safety","","Objective_2"
"OBJ3","To assess the dose-dependent improvement in behavior. Improved scores on the Revised Neuropsychiatric Inventory (NPI-X) will indicate improvement in these
areas.","43b2e144-2cd6-4380-b52b-9919dcd034ce","Objective","Behaviour","","Objective_3"
"OBJ4","To assess the dose-dependent improvements in activities of daily living. Improved scores on the Disability Assessment for Dementia (DAD) will indicate improvement in these areas (see Attachment LZZT.5).","a86eb5ef-de62-4aa3-aeeb-3e143b52fd05","Objective","","","Objective_4"
"OBJ5","To assess the dose-dependent improvements in an extended assessment of cognition that integrates attention/concentration tasks. The Alzheimer's Disease Assessment Scale-14 item Cognitive Subscale, hereafter referred to as ADAS-Cog (14), will be used for this assessment (see Attachment LZZT.2).","64b576b7-a577-4053-a7c3-9f94b639170e","Objective","","","Objective_5"
"OBJ6","To assess the treatment response as a function of Apo E genotype.","6dfadef3-643f-43ba-991d-6fe960b59a68","Objective","","","Objective_6"
